Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings

We recently published 10 Stocks Exploding Higher: Bitcoin Miners Dominate the List. Summit Therapeutics Inc. (NASDAQ:SMMT) is one of Wednesday’s top performers.

Summit Therapeutics surged by 16.05 percent on Wednesday to close at $28.27 apiece, leading the rally of the overall biotechnology sector, as investors repositioned portfolios ahead of the release of its second quarter earnings performance.

Based on its historical earnings reporting dates, Summit Therapeutics Inc. (NASDAQ:SMMT) is slated to announce the results of its financial and operating performance in the first week of August 2025, where investors will be looking out for updated outlooks and cues of further partnerships with other companies.

In recent news, Summit Therapeutics Inc. (NASDAQ:SMMT) reportedly sat down with AstraZeneca for a supposed $15-billion licensing deal for its experimental lung cancer drug Ivonescimab.

According to reports, the deal could include an upfront payment of several billion dollars to Summit Therapeutics Inc. (NASDAQ:SMMT) on top of milestone payments later on. However, a deal is not guaranteed as the company could still explore partnerships with other firms.

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings

A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample.

The negotiations followed Summit Therapeutics Inc.’s (NASDAQ:SMMT) official $5-billion licensing partnership with China-based Akeso in December 2022.

While we acknowledge the risk and potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.